• NIH collaboration aims to identify, validate immunotherapy biomarkers

    11 monthes ago - By Healio

    NIH launched the Partnership for Accelerating Cancer Therapies, a 5-year public-private research collaboration.
    The $215 million effort is part of the national cancer moonshot initiative.
    The collaboration - managed by the Foundation for the National Institutes of Health and advised by the FDA - will focus on efforts to identify, develop and validate robust biomarkers to advance new immunotherapy treatments for cancer care.
    “The purpose is to find better ways to predict which patients may benefit from such therapies, and to design new approaches for those who don't,”
    Read more ...